ArticleScientific reports2021
Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway.
Kensuke Hachiya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it